---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-041325"
form_type: "8-K"
ticker: "NKTR"
cik: "0000906709"
company_name: "NEKTAR THERAPEUTICS"
filed_at: "2024-05-09T23:59:59+00:00"
generated_at: "2026-06-02T08:10:35.751702+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Nektar Q1 net loss narrows to $36.8M; REZPEG Phase 2b on track for H1 2025 data

## Summary
- Revenue flat at $21.6M; net loss of $36.8M ($0.19/share) vs $137M loss YoY, improved on lower costs.
- Cash and securities $326M; expects to fund operations into Q3 2026.
- R&D expense $27.4M, down from $30.5M YoY; G&A $20.1M vs $21.1M.
- Phase 2b REZPEG studies in atopic dermatitis and alopecia areata enrolling; topline data H1 2025.
- Raised $30M gross via private placement in March 2024 with TCG Crossover Fund.

## SEC filing metadata
- accession: 0001213900-24-041325
- form_type: 8-K
- ticker: NKTR
- cik: 0000906709
- company_name: NEKTAR THERAPEUTICS
- filed_at: 2024-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/906709/000121390024041325/0001213900-24-041325-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/906709/000121390024041325/ea0205626-8k_nektar.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-041325
- JSON: https://secwatch.observer/filing/0001213900-24-041325.json
- Plain text: https://secwatch.observer/filing/0001213900-24-041325.txt

## Key facts
- Earnings Releases
  NEKTAR THERAPEUTICS reported first quarter ended March 31, 2024 results: revenue $21.6 million, net income $36.8 million or $0.19 basic and diluted loss per share, EPS $0.19 basic and diluted loss per share.
  - Period: first quarter ended March 31, 2024
  - Revenue: $21.6 million
  - Net income: $36.8 million or $0.19 basic and diluted loss per share
  - EPS: $0.19 basic and diluted loss per share
  - Result: reported results
  source text: the TNFR2 receptor is progressing through IND-enabling studies to support entering the clinic next year.” Summary of Financial Results Revenue in the first quarter of 2024 was $21.6 million as compared to the same $21.6 million in the first quarter of 2023. Total operating costs and expenses in the first quarter of 2024 were $57.1 million as compared to $156.3
  evidence_url: https://www.sec.gov/Archives/edgar/data/906709/000121390024041325/0001213900-24-041325-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.